Second-Line Protease Inhibitor-Based Haart after Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in Asian HIV-Infected Children

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antiviral Therapy

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3851/IMP2494PMID 23296119PMCID PMC3715593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting

  2012cited by this paper
• Risk of triple-class virological failure in children with HIV: a retrospective cohort study

  2011cited by this paper
• Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors

  2011cited by this paper
• COHORT PROFILE Cohort Profile : The TREAT Asia Pediatric HIV Observational Database

  2011cited by this paper
• First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

  2011cited by this paper
• Effect of Specific ART Drugs on Lipid Changes and the Need for Lipid Management in Children With HIV

  2011cited by this paper
• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa

  2011cited by this paper
• Antiretroviral Therapy Outcomes of HIV-Infected Children in the TREAT Asia Pediatric HIV Observational Database

  2010cited by this paper
• Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.

  2010cited by this paper
• Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.

  2010cited by this paper
• Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).

  2010cited by this paper
• Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children

  2010cited by this paper
• The effectiveness of highly active antiretroviral therapy among HIV-infected children in Asian countries

  2010cited by this paper
• The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE).

  2009cited by this paper
• HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

  2009cited by this paper
• Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ ritonavir, in pretreated children at 96 weeks

  2009cited by this paper
• Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy

  2009cited by this paper
• Morphologic and metabolic abnormalities in vertically HIV-infected children and youth

  2009cited by this paper
• Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

  2009cited by this paper
• Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières

  2008cited by this paper
• The triglyceride/HDL‐cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors

  2008cited by this paper
• Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

  2008cited by this paper
• Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.

  2008cited by this paper
• Cardiovascular risk factor levels and their relationships with overweight and fat distribution in children: the Fleurbaix Laventie Ville Santé II study.

  2007cited by this paper
• Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir.

  2007cited by this paper
• Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

  2007cited by this paper
• Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

  2007cited by this paper
• Predictive Factors of Virologic Success in HIV-1–Infected Children Treated With Lopinavir/Ritonavir

  2004cited by this paper
• Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.

  2004cited by this paper
• 2000 CDC Growth Charts for the United States: methods and development.

  2002cited by this paper
• CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000

  2002cited by this paper
• National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.

  1992cited by this paper
• Highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. National Cholesterol Education Program Expert Panel on Blood Cholesterol Levels in Children and Adolescents.

  1992cited by this paper

• Incidence and predictors of virological failure among HIV infected children and adolescents receiving second-line antiretroviral therapy in Uganda, a retrospective study

  2024cites this paper
• Thirteen-year viral suppression and immunologic recovery of LPV/r-based regimens in pediatric HIV treatment: a multicenter cohort study in resource-constrained settings of China

  2023cites this paper
• Outcomes of second‐line antiretroviral therapy among children living with HIV: a global cohort analysis

  2020cites this paper
• The Lipodystrophy Syndrome in HIV-Infected Children under Antiretroviral Therapy: A First Report from the Central Africa

  2019cites this paper
• Simultaneous quantitation of zidovudine, efavirenz, lopinavir and ritonavir in human hair by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.

  2018cites this paper
• Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.

  2017cites this paper
• Making things easier. How to improve antiviral drug treatment for children

  2016cites this paper
• Metabolic and Renal Adverse Effects of Antiretroviral Therapy in HIV-infected Children and Adolescents

  2015cites this paper
• Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

  2015cites this paper
• Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children

  2015cites this paper
• Mucoadhesive thermo-responsive chitosan-g-poly(N-isopropylacrylamide) polymeric micelles via a one-pot gamma-radiation-assisted pathway.

  2015cites this paper
• Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.

  2015cites this paper
• The changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents

  2013cites this paper